AbbVie Q4 Earnings Beat and 13.8% Share Rally Driven by New Immunology Launches
AbbVie beat fourth-quarter estimates for both earnings and sales, driving a 13.8% share gain over the past six months against a 29.5% industry gain. New immunology launches Skyrizi and Rinvoq, plus its neuroscience portfolio and recent acquisitions, are expected to sustain top-line growth despite Humira LOE and oncology headwinds.
1. Q4 Performance and Share Gains
AbbVie reported fourth-quarter earnings and sales that exceeded analyst estimates, contributing to a 13.8% share price increase over six months compared with a 29.5% industry gain. The company also delivered robust net sales growth in 2025, marking the second full year of recovery following Humira’s loss of exclusivity in the U.S.
2. Immunology Launches and Pipeline Strategy
The launches of Skyrizi and Rinvoq have demonstrated strong uptake, supported by recent approvals in new indications. AbbVie's neuroscience portfolio further bolsters revenue, while a series of acquisitions over the past two years aims to strengthen its early-stage pipeline for future growth.
3. Headwinds and Growth Outlook
Despite the positive trends, AbbVie faces lingering pressures from Humira LOE, slowing oncology sales and macroeconomic challenges impacting its aesthetics business. Management’s strategy will focus on balancing ongoing product launches with cost discipline to navigate these headwinds and sustain top-line momentum.